

CURRICULUM VITAE Donato Agnusdei, MD

1. Personal Information

- a. Sex: Male
- b. Date of Birth: December 15, 1949
- c. Place of birth: Foggia, Italy

2. Present Position: Medical Fellow – Director , Global Medical External Relations Bone Muscle & Joint Platform Team – Eli Lilly & Company, Florence, Italy

3. Education:

a. Undergraduate/Graduate

11/1968–07/1974: Laurea in Medicina e Chirurgia (Degree in Medicine and Surgery Diploma, undergraduate/graduate combined program) Siena University, School of Medicine, Siena Italy
Date of graduation: 07/19/1974
Grade: 110/110 cum laude

b. Postgraduate:

11/1974 – 4/1977: School of Specialization in Cardiovascular Diseases, Siena University, School of Medicine, Siena Italy
Date of graduation: 04/16/1977
Grade: 70/70 cum laude

08/1974 –09/1976: Fellowship in Internal Medicine,
Institute of Medical Semeiotics , Siena University, School of
Medicine, Siena
Director: Tullio di Perri, MD

10/1976 –09/1979: Assistant in Internal Medicine,
Ospedale S. Cristofano, Montepulciano, Siena

10/1976 - 09/1979: Assistant in Emergency Department,
University Hospital, University of Siena, Siena

11/1990 - 7/1995: School of Specialization in Endocrinology,
Siena University, School of Medicine, Siena
Date of graduation: 11/07/1995
Grade: 70/70

5. Academic Position/Employment:

Assistant Professor of Medicine, 1980-1996
Institute of Internal Medicine - University of Siena

6. Board Certification:

Italian Board of Specialty in Cardiology: 1977
Italian Board of Specialty in Endocrinology: 1995

7. Editorial Responsibilities:

Journal of Endocrinological Investigation: 1989 - 2006
Clinica delle Malattie dell'Osso: 1988 - 1995
Italian Journal of Bone and Electrolyte Metabolism 1990 - 2003

8. Professional Societies and Organizations:

American Society for Bone and Mineral Research, since September 1988
International Bone Mineral Society, since April 1990
European Calcified Tissue Society, since March 1990
The Endocrine Society, since January 1995
Italian Society for Mineral Metabolism, since 1985
Italian Society for Osteoporosis & Metabolic Bone Diseases, since 1988
Italian Society of Cardiology, 1984 - 1996
Member of the Executive committee of the Committee of Corporate
Advisors, International Osteoporosis Foundation 1996 - 2007

9. Consulting Relationships and Board Memberships:

Project Management Group of European Vertebral Osteoporosis Study
(EVOS), 1990 - 2001
Project Management Group of European Prospective Osteoporosis Study
(EPOS), 1994 - 2003
Member of the Working party of IOF on Quality of Life in Osteoporosis
(QUALEFFO), 1995 - 2002

Member of the Working Group for the production of the European Union Report "Osteoporosis -Action for Prevention, 1998

Member of the Committee of Scientific Advisors (CSA), International Osteoporosis Foundation (IOF) 2007 - present

Member of the Scientific Board of the European Society of Clinical and Economic Aspect of Osteoporosis and Osteoarthritis (ESCEO) - 2007 - present

Member of the Scientific Board of the International Society of Musculoskeletal and Neuronal Interactions (ISMNI) - 2007 - present

10. Clinical Title and Responsibilities:

Assistant Professor of Medicine

Attending Physician in the Institute of Internal Medicine and Medical Pathology, University Hospital, Siena

Consultant, Bone Mineral Metabolism Service

Institute of Internal Medicine, Siena

11. Teaching Title and Responsibilities:

Assistant Professor of Medicine

Teacher:

Clinical Biochemistry: 4th year Medical School, University of Siena

Parathyroid Diseases: 4th year Medical School, University of Siena

Medical Emergency: 6th year Medical School, University of Siena

Postgraduate School of Sinology 1999 - University of Siena

Master in Metabolic Bone Diseases, University of Florence 2005 - 2007

12. Bibliography:

a. Peer-reviewed Manuscripts: 80+

b. Invited Publications: 128

c. Chapters of books: 10

d. Book Editor 1

13. Research Areas & Scientific Activities:

During the years spent in Academia Dr. Agnusdei's research interests have been mainly oriented toward the pathogenesis of postmenopausal osteoporosis, and the role of estrogens and intestinal calcium absorption; the use of markers of bone turnover in the diagnosis and treatment of the disease; and the new modalities and therapeutic strategies for the osteoporotic syndromes. He has been also investigator and study coordinator in several international clinical trials aimed to investigate the effects of bone active drugs, including, calcium

and vitamin D, calcitonin, HRT, bisphosphonates, ipriflavone and SERMs in the treatment of primary and secondary osteoporosis.

Starting June 1st 1996, Dr. Agnusdei joined the Raloxifene Heavyweight Team at the Regional Business Unit for skeletal diseases of Eli Lilly & Co., based in Florence, Italy. In this position Dr. Agnusdei has been in charge for all the medical activities in Europe dealing with skeletal diseases. In particular he played a crucial role in supporting the regulatory European Team for the registration of the SERM Raloxifene for the prevention and treatment of Osteoporosis. During this process he has been involved in the preparation of the expert reports submitted to the Agency, and in the discussion of two oral hearings requested by the CHMP before granting the marketing authorization (MAA) of Raloxifene. In the following year, Dr. Agnusdei played a significant role in the preparation, submission and discussion of the "reimbursement dossier" for Evista to the Italian Drug Agency (CUF). At the same time Dr. Agnusdei has been deeply involved in the clinical development of new bone forming agents, such as parathyroid hormone peptides. Dr. Agnusdei has been part of the corporate group for the submission of the Teriparatide (For(s)teo) dossier to the CHMP that granted the MAA for the use in patients with established osteoporosis. To this end, Dr. Agnusdei has been fully committed to the implementation of different projects aimed to the commercialization and reimbursement of PTH in Europe and Latin America

After joining Eli Lilly, Dr. Agnusdei continued to be extensively involved in presentations at International meetings in the bone field presenting the clinical data of SERMs, and PTH.

In March 2000, Dr. Agnusdei has been appointed as European Product Team Physician for Raloxifene and Teriparatide. In this role Dr Agnusdei has been coordinating all the post-registration activities of Teriparatide, including phase IV studies and compliance programs across Europe.

Starting November 1, 2001, Dr. Agnusdei has been appointed as "Global Medical Advisor Osteoporosis" for Europe & Latin America. In this position Dr Agnusdei has extended his activities to include Latin America, focusing mainly on major countries, such as Mexico and Brasil.

In November 2004, Dr Agnusdei has been promoted to the current position of Medical Fellow I for Osteoporosis. In this capacity, Dr Agnusdei changed his focus and currently is the scientific manager of all Lilly events worldwide (Global Medical Conferences, Regional Medical Conferences, Lilly Symposia, Global and Regional Advisory Boards, Osteoporosis Excellence Meetings, etc.). In addition Dr Agnusdei has taken the responsibility for a project called Thought Leaders initiative; namely, coordinate the worldwide relationships with 50 TLs in the postmenopausal women's health arena, and represent the Company in all the

events and with all the organizations and scientific societies (see point 9). He has been also part of a group responsible for the submission to the FDA of the "breast cancer prevention/risk reduction for Evista. Indication has been granted on March 2008.

In 2010 and 2011 Dr Agnusdei has been invited by Eli Lilly Japan to support the launch of Forteo in that country. The launch occurred in October 2010 and has been the most successful launch for Forteo worldwide.

In 2013 Dr Agnusdei has been invited again from Eli Lilly Japan for two projects: sustain the commercialization of Forteo and re-launch of Evista that the affiliate took back from Chugai Pharmaceuticals at the end of the co-marketing agreement.

In 2014 Dr Agnusdei has been supporting affiliates in EMBU such as China and Russia.

The inputs provided by Dr Agnusdei to regional and global business plans, across all the roles he has covered in Lilly, have been greatly appreciated by the marketing function, mainly for the strategic vision they have offered to the management of the Platform Team.

Starting April 1, 2015, Dr Agnusdei has retired as full time employee of Eli Lilly and Company. Currently is self-employed and CEO of "Donato's Scientific Consulting". He has signed in the last 3 years a consulting, non binding, contract with Eli Lilly. In addition, starting in 2017 he has been elected as member of the board of Fragility Fracture Network for a 2 years term.